Looks like the HMGoG and GHA plan to push Molnupiravir -
The GHA is closely monitoring the UK’s rollout of a new anti-viral pill for Covid-19 that can be taken at home and which health officials want to make available here too.
The drug, called molnupiravir, is for people who have had a positive Covid test and have at least one risk factor for developing severe illness, such as obesity, being over the age of 60, diabetes or heart disease.
It will be “a gamechanger” for the most vulnerable people who contract Covid-19, the UK Government has said.
The UK’s Medicines and Healthcare products Regulatory Agency [MHRA] said last month that the drug is safe and effective at reducing the risk of hospital admission and death in people with mild to moderate Covid who are at extra risk from the virus.
But while the MHRA approved the drug, the pill has yet to be offered to UK patients by the NHS.
This means it's incoming.
Beware:
https://accessh.org/press/harming-those-who-receive-it-the-dangers-of-molnupiravir-part-2/
UK Gov – Lagevrio 200 mg hard capsules molnupiravir – Patient Information Leaflet for Lagevrio - GOV.UK
Package leaflet: Information for the user
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. ou must not be given Lagevrio:
Do not give this medicine to children and adolescents aged less than 18 years. The use of Lagevrio in persons aged less than 18 years has not yet been studied.
Animal studies with molnupiravir have shown harmful effects to the unborn animal.